As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Progressive Gonorrhea– pipeline landscape globally. Progressive Gonorrhea Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:https://www.globalinsightservices.com/request-sample/GIS31228
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix.
Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one testicle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain.
Diagnosis of Gonorrhea can be done after analyzing a sample of cells. Samples can be collected by urine test or swab of affected area.
Treatment for Gonorrhea include one-time intramuscular injection of the antibiotic ceftriaxone.
Some companies that are active in the development of gonorrhea drugs include Evofem Inc., GlaxoSmithKline, and Entasis Therapeutics.
There are several clinical trials currently ongoing in gonorrhea drug development. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing vaccine candidates against gonorrhea. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Gonorrhea treatment such as EVO100, Gepotidacin, Zoliflodacin and others. Key players involved in the development of therapies to treat Gonorrhea are Alopexx Pharmaceuticals Inc, Biolytics Pharma, Entasis Therapeutics, Evofem Inc, GlaxoSmithKline and others. Three drugs are under late-stage Phase III clinical trials and some other drugs are under preclinical and discovery stages of development.
Report Highlights
Global Insight Service’s, Gonorrhea – Drug Pipeline Landscape, 2023 report provides an overview of the Gonorrhea pipeline drugs. This report covers detailed insights on Gonorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gonorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Buy Now:https://www.globalinsightservices.com/checkout/single_user/GIS31228
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/